about
BRCAness: finding the Achilles heel in ovarian cancerNew advances in targeted gastric cancer treatmentBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsDouble threading through DNA: NMR structural study of a bis-naphthalene macrocycle bound to a thymine-thymine mismatchDiscovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2 H )-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 InhibitorsPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineATM Kinase Is Required for Telomere Elongation in Mouse and Human CellsPARP inhibitor treatment in ovarian and breast cancerEnhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for CancerAGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast CancerPhase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinomaPARP inhibitors: its role in treatment of cancer.Targeting DNA repair pathways for cancer treatment: what's new?Ganoderma lucidum extract induces G1 cell cycle arrest, and apoptosis in human breast cancer cells.CSNK1E/CTNNB1 are synthetic lethal to TP53 in colorectal cancer and are markers for prognosisPARP-1 inhibitors DPQ and PJ-34 negatively modulate proinflammatory commitment of human glioblastoma cells.Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer.ARTD1-induced poly-ADP-ribose formation enhances PPARγ ligand binding and co-factor exchangeCurrent status of novel agents in advanced gastroesophageal adenocarcinoma.RAS transformation requires CUX1-dependent repair of oxidative DNA damage.SWI/SNF complexes are required for full activation of the DNA-damage response.Drug therapy for hereditary cancersPoly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury.Combining emerging agents in advanced breast cancerOptimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogenePast, present, and future challenges in breast cancer treatment.Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors.Poly-ADP-ribose-polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of type 2 diabetes.Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.Targeting the LKB1 tumor suppressor.Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.Reverse the Resistance to PARP Inhibitors.LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors.Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma
P2860
Q24630872-F545831B-7317-4C15-9BCA-D3897101E43CQ26738548-4B89BA77-0C36-4DBA-8710-76A7A6ABEFD9Q26852274-CCE78B76-0231-404F-A73E-4CDD5A6AE5A0Q27677452-AC54CC1E-EE65-49ED-9B3C-D8702BE8F37EQ27684311-405DD8A1-4E47-459D-8052-EFDA31700096Q28072204-39DA22CB-CAA4-44D2-978B-03A572A94BD0Q28114948-33684BD2-D3F4-4D91-8BE3-F572CAEE02EEQ28741688-DEAF6740-DBC9-44CA-9C82-891F010E1A98Q29147555-7A4318E2-47B2-4689-9864-63D6457CA71AQ30318240-DE99142D-4B4E-4749-B318-92CD01787475Q31132980-D784900E-1152-4768-9BF1-E440567759F0Q33426556-5B65E867-DDF7-4177-8A0F-6FCDF3FE12FAQ33579740-F3026EC9-E762-4C1D-9821-19FD065CD276Q34015040-99B55AB4-2885-4E4E-8699-2496F2BFB8F7Q34320794-9D8C962E-DB59-4E92-910E-CD459AD97278Q34346431-83071C07-2FCC-4746-AA3E-2FFBE71599AFQ34421470-1F29F478-7EC0-4DAC-86DB-929D1B735DC8Q34833628-A50F5E26-D9D3-4A55-95EF-EF61B83410ADQ34883050-33BEA06B-BACF-4A85-95AF-9D38F7CA5FEBQ34962039-51DB6ED2-E8A3-4513-95DA-C7E89FB4F8F5Q35117739-49EA8B23-B220-450D-9B02-9DD5CD55CEB4Q35176127-AA069ABB-EC1D-4039-BDED-4928430E65E0Q35208929-302DF229-4B66-4A8F-9104-FE4E5692FB33Q35514172-41083BB1-F4D6-414D-BA62-1D04C0D88972Q35584962-CE7D237F-0DC8-41DF-8E3C-471081E395EEQ35837949-2C2FED7B-43C0-445A-934F-D97BDC597634Q35976084-306985E0-C1B6-4B11-A1BD-D3D98D8C9D67Q36110001-42F35632-CBD7-428B-AA91-801AC316296AQ36387871-F137C16F-1282-4DFA-A11C-F62BED40046FQ36413813-C3DEFCD6-440F-4032-8ADC-A3E2164082D1Q36934273-970EAC26-DC74-41DF-8250-1C717750D484Q37092210-E5129FE6-2134-43BC-91F6-A08009FEC994Q37172217-1457840C-7E7C-4D6A-8718-BF42D8774227Q37475476-21A5BAF3-60E2-405E-88A8-E4B92419DD0DQ37506032-7A4C96A2-C72B-4B6F-893B-27BEF3F75BFFQ37524037-778DF23E-7B12-44BF-98B6-6EF7A58446CBQ37553978-D2999F4A-C066-4AD1-A128-29CEF42C3FC4Q37675896-B73B5835-2E1C-480F-86F1-0A30E87040BDQ37687396-60E0BC90-B699-4E36-B5AB-CAFC69054896Q37687452-327DA899-FB1A-4885-B292-B58C3587A5D9
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A review of PARP inhibitors: from bench to bedside.
@en
A review of PARP inhibitors: from bench to bedside.
@nl
type
label
A review of PARP inhibitors: from bench to bedside.
@en
A review of PARP inhibitors: from bench to bedside.
@nl
prefLabel
A review of PARP inhibitors: from bench to bedside.
@en
A review of PARP inhibitors: from bench to bedside.
@nl
P2093
P2860
P356
P1433
P1476
A review of PARP inhibitors: from bench to bedside.
@en
P2093
C Underhill
H Bonnefoi
M Toulmonde
P2860
P304
P356
10.1093/ANNONC/MDQ322
P577
2010-07-19T00:00:00Z